js","9180","static/chunks/9180-141aeb8e4de0fb19.js","9897","static/chunks/9897-96ec494a15704266.js","4005","static/chunks/4005-f97caa47699c0d92.js","855","static/chunks/855-cf19c6c21b03f067.js","5208","static/chunks/5208-62bc554de8278993.js","1094","static/chunks/1094-e2bede973ee0fcba.js","261","static/chunks/261-62d59822d4693e14.js","105","static/chunks/105-0cf779e7b5058905.js","3204","static/chunks/3204-771fe8926763857e.js","2222","static/chunks/2222-1c9ea13d7c66a834.js","6553","static/chunks/6553-e3b40c5195b8a3ba.js","3864","static/chunks/3864-e65f5ab7d1e2b87f.js","6936","static/chunks/6936-95130c4492d838b4.js","8678","static/chunks/8678-a0502ad698b1d653.js","9781","static/chunks/9781-cfd3d6d9018cf1de.js","5181","static/chunks/5181-7cb9d448d4c5f6b5.js","1730","static/chunks/1730-e164aa8f11e16aba.js","7755","static/chunks/7755-a0da8883abfcfd81.js","7946","static/chunks/7946-aed52829e81f011b.js","8422","static/chunks/8422-2eeeb4781ba7854c.js","9077","static/chunks/9077-b99ded772bea5001.js","4586","static/chunks/4586-5c6c0d849ced3727.js","1324","static/chunks/1324-0939666a4c952298.js","7107","static/chunks/7107-4c801ae286d6095d.js","4755","static/chunks/4755-26f5ea982e5cd928.js","5458","static/chunks/app/dashboard/episodes/%5Bid%5D/page-aba7b83b4fc25034.js"],"EpisodeRecommend"] 24:T67e,

Dutch biotech Merus’ EGFR x LGR5 bispecific antibody has caught investors’ attention in the run-up to ASCO as a new approach to block EGFR signaling. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss Phase II data from Merus for petosemtamab as they preview the American Society of Clinical Oncology’s upcoming annual meeting. The analysts also assess a setback in a gene therapy trial for Rocket Pharmaceuticals, renewed interest in cancer target EpCAM, and a flurry of biopharma

Ep. 299 - ASCO, EpCAM, Rocket & HK IPOs

BioCentury This Week